Tags

Type your tag names separated by a space and hit enter

Non-alcoholic fatty liver disease.
J Diabetes 2012; 4(3):266-80JD

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It is closely associated with metabolic syndrome. The alarming epidemics of diabetes and obesity have fueled an increasing prevalence of NAFLD, particularly among these high-risk groups. Histologically, NAFLD encompasses a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which is characterized by hepatocyte injury, inflammation, and variable degrees of fibrosis on liver biopsy. Non-alcoholic steatohepatitis can progress to cirrhosis in a fraction of patients. There is currently little understanding of risk factors for disease progression and the disease pathogenesis has not been fully defined. Liver biopsy remains the gold standard for diagnosis. Weight loss, dietary modification, and the treatment of underlying metabolic syndrome remain the mainstays of therapy once the diagnosis is established. There are no well-established pharmacological agents for treatment of NASH, although this is a subject of ongoing research.

Authors+Show Affiliations

Rockefeller University, New York, NY, USA. atuyama@mail.rockefeller.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22564417

Citation

Tuyama, Ana C., and Charissa Y. Chang. "Non-alcoholic Fatty Liver Disease." Journal of Diabetes, vol. 4, no. 3, 2012, pp. 266-80.
Tuyama AC, Chang CY. Non-alcoholic fatty liver disease. J Diabetes. 2012;4(3):266-80.
Tuyama, A. C., & Chang, C. Y. (2012). Non-alcoholic fatty liver disease. Journal of Diabetes, 4(3), pp. 266-80. doi:10.1111/j.1753-0407.2012.00204.x.
Tuyama AC, Chang CY. Non-alcoholic Fatty Liver Disease. J Diabetes. 2012;4(3):266-80. PubMed PMID: 22564417.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Non-alcoholic fatty liver disease. AU - Tuyama,Ana C, AU - Chang,Charissa Y, PY - 2012/5/9/entrez PY - 2012/5/9/pubmed PY - 2013/2/5/medline SP - 266 EP - 80 JF - Journal of diabetes JO - J Diabetes VL - 4 IS - 3 N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It is closely associated with metabolic syndrome. The alarming epidemics of diabetes and obesity have fueled an increasing prevalence of NAFLD, particularly among these high-risk groups. Histologically, NAFLD encompasses a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which is characterized by hepatocyte injury, inflammation, and variable degrees of fibrosis on liver biopsy. Non-alcoholic steatohepatitis can progress to cirrhosis in a fraction of patients. There is currently little understanding of risk factors for disease progression and the disease pathogenesis has not been fully defined. Liver biopsy remains the gold standard for diagnosis. Weight loss, dietary modification, and the treatment of underlying metabolic syndrome remain the mainstays of therapy once the diagnosis is established. There are no well-established pharmacological agents for treatment of NASH, although this is a subject of ongoing research. SN - 1753-0407 UR - https://www.unboundmedicine.com/medline/citation/22564417/Non_alcoholic_fatty_liver_disease_ L2 - https://doi.org/10.1111/j.1753-0407.2012.00204.x DB - PRIME DP - Unbound Medicine ER -